Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer.
Overexpression or/and activating mutation of FLT3 kinase play a major driving role in the pathogenesis of acute myeloid leukemia (AML). Hence, pharmacologic inhibitors of FLT3 are of therapeutic potential for AML treatment. In this study, BPR1J-340 was identified as a novel potent FLT3 inhibitor by...
Main Authors: | Wen-Hsing Lin, Teng-Kuang Yeh, Weir-Torn Jiaang, Kuei-Jung Yen, Chun-Hwa Chen, Chin-Ting Huang, Shih-Chieh Yen, Shu-Yi Hsieh, Ling-Hui Chou, Ching-Ping Chen, Chun-Hsien Chiu, Li-Chun Kao, Yu-Sheng Chao, Chiung-Tong Chen, John T-A Hsu |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3885398?pdf=render |
Similar Items
-
The HDAC Inhibitor Vorinostat Diminishes the In Vitro Metastatic Behavior of Osteosarcoma Cells
by: Xiaodong Mu, et al.
Published: (2015-01-01) -
Overcoming Resistance to FLT3 Inhibitors in the Treatment of <i>FLT3</i>-Mutated AML
by: Stephen S.Y. Lam, et al.
Published: (2020-02-01) -
Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
by: Mark C Weir, et al.
Published: (2017-01-01) -
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
by: Musa Yilmaz, et al.
Published: (2020-10-01) -
Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
by: Musa Yilmaz, et al.
Published: (2021-02-01)